Previous 10 | Next 10 |
Sinovac Biotech's (SVA) coronavirus vaccine has passed the 50% threshold for efficacy in late-stage trials in Brazil, WSJ reports.Considering these results, regulators can give it the green light for use, said people involved in its development.Brazil is the first country to complete Phase 3 ...
Singapore is poised to become Asia's first country to receive Pfizer (PFE), BioNTech's (BNTX) coronavirus vaccine, report.Prime Minister Lee Hsien Loong, in a televised address, said the first doses are due to arrive later in December, and that other vaccines would also be coming in the month...
JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. Beijing's Sinovac Biotech reported Sino Biopharma of Hong Kong will invest $515 million in a Sinovac subsidiary to dou...
Sinovac Biotech has developed a successful COVID-19 vaccine, CoronaVac, directly competing with two Chinese rivals, Pfizer, AstraZeneca, Moderna and Russia's Sputnik V. Nasdaq and Hong Kong-listed partner Sino Biopharm providing $515 million funding for 15.03% equity stake in Sinovac....
Hong Kong has reached agreements with two COVID-19 vaccine manufacturers, securing 15M shots, the first batch of vaccine to be available as early as January 2021 - Bloomberg.The government will purchase 7.5M doses of the mRNA shot developed by Pfizer (PFE) and BioNTech (BNTX) and 7.5M shots f...
Sinovac Biotech (SVA) has announced that the China National Medical Products Administration has approved and issued a product license for the 23-Valent Pneumococcal Polysaccharide Vaccine to prevent the infection by streptococcus pneumonia in adults and children ages 2 years old and above. Mr...
Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the China National Medical Products Administration (NMPA) has approved and issued a Product license for the Company...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter and Nine Months End...
Sinovac Biotech's (SVA) subsidiary, Sinovac Life Sciences has secured ~$500M in funding for further development, capacity expansion and manufacturing of the CoronaVac, its COVID-19 vaccine candidate, as well as conduct other development and operational activities.The investment was made in ex...
China's Sinovac Biotech's (SVA) experimental COVID-19 vaccine, CoronaVac triggered a quick immune response but low levels of antibodies when compared to the people who had recovered from the disease, source Reuters.While the early to mid-stage trials were not designed to assess the efficacy o...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerativ...
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023. The annual r...
--News Direct-- Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 –...